NEWVectors or files. Pick a path.Start →
    Back to All Lists

    Best AI Medical Imaging Platforms in 2026

    An overview of AI platforms for medical image analysis, including radiology AI, pathology, and clinical image management. Covers FDA clearance status, clinical validation, and integration with healthcare systems.

    Ethan Steininger
    Published · Updated
    Last tested: November 10, 2026
    10 tools evaluated

    Skip the research? Mixpeek runs AI medical imaging on your own data: extraction, indexing, and search in one platform.

    Run it on your own data, free

    Key Takeaways

    • Aidoc ranks first, best for hospitals and radiology departments needing AI-assisted triage for critical findings. Largest FDA-cleared triage portfolio on this list (35 FDA AI device list entries as of September 2026), plus a cleared foundation model that triages multiple CT findings from one model, all running as a single always-on background layer.
    • Viz.ai is second, best for stroke centers and hospitals needing AI-powered neurovascular triage with proven outcomes. Care coordination built into the product: not just detection but automated team notification and workflow orchestration that directly reduces time-to-treatment.
    • Mixpeek ranks #9, best for research teams and health-tech companies building non-diagnostic imaging tools such as similar-case retrieval for research and training data management.
    • We ranked 10 options on clinical accuracy (35%), regulatory status (25%), integration (20%) and deployment flexibility (20%). Prices and claims were checked against each vendor's public pages in November 2026.

    Skip the comparison? Mixpeek runs AI medical imaging on your own data: extraction, indexing, and search in one platform.

    How We Evaluated

    Evaluated by the Mixpeek engineering team, who build and operate multimodal retrieval infrastructure in production. Last tested November 2026; rankings re-checked when the market shifts, with pricing and claims verified against each vendor's public documentation.

    Clinical Accuracy

    35%

    Sensitivity, specificity, and validation against clinical outcomes for diagnostic tasks.

    Regulatory Status

    25%

    FDA clearance, CE marking, and compliance with healthcare regulations (HIPAA, GDPR).

    Integration

    20%

    Compatibility with PACS, EHR systems, and standard medical imaging formats (DICOM).

    Deployment Flexibility

    20%

    On-premise, cloud, and hybrid deployment options for different healthcare IT environments.

    Quick answer

    The short version, before the detail:

    • Aidocbest for hospitals and radiology departments needing ai-assisted triage for critical findingsLargest FDA-cleared triage portfolio on this list (35 FDA AI device list entries as of September 2026), plus a cleared foundation model that triages multiple CT findings from one model, all running as a single always-on background layer.
    • Viz.aibest for stroke centers and hospitals needing ai-powered neurovascular triage with proven outcomesCare coordination built into the product: not just detection but automated team notification and workflow orchestration that directly reduces time-to-treatment.
    • PathAIbest for pathology labs and pharmaceutical companies needing ai-assisted tissue analysis and biomarker researchCombines an FDA-cleared primary diagnosis platform (AISight Dx) with biomarker scoring tools used in drug development by most of the top 15 biopharma companies, per PathAI.
    • Tempusbest for health systems wanting ai that combines imaging with genomic and clinical data for precision medicinePairs radiology and pathology imaging AI with genomic sequencing and a large clinical data library in one vendor, which few imaging companies can match.
    • Google Health AI (MedGemma)best for research teams and developers building and validating their own medical imaging modelsOpen, multimodal medical models you can fine-tune and host yourself, backed by Google's research on retinal screening and medical AI.
    • Paigebest for clinical pathology labs wanting fda-authorized ai assistance for prostate biopsy reviewHolds the first FDA marketing authorization for an AI pathology product and now draws on Tempus's library of almost 7 million de-identified pathology slides.
    • Tempus Pixel (formerly Arterys)best for cardiac imaging centers and oncology practices needing cloud-based ai for mr analysis and lesion trackingAn early cloud-based medical image analysis platform, now tied into Tempus's oncology data and pathology products.
    • Lunitbest for hospitals and screening programs needing fda-cleared ai for chest x-ray and mammography with strong global validation dataLarge global footprint (10,000+ customer sites, per Lunit) and a deep publication record across chest X-ray and breast imaging, plus pathology tools for oncology research.

    Overview

    The AI medical imaging market is split between radiology triage vendors like Aidoc and Viz.ai, which hold long lists of FDA clearances and publish outcome studies, and broader platforms like Tempus that combine imaging with molecular and clinical data. Pathology is its own sub-market: Tempus bought Paige in 2025, and Roche agreed in May 2026 to acquire PathAI. Google now offers open developer models (MedGemma) in place of its retired MedLM API. The FDA's AI-Enabled Medical Device List held 1,614 entries at its September 2026 update, 1,230 of them in radiology. For teams building custom imaging applications such as similar-case retrieval, training data curation or research pipelines, a general multimodal platform like Mixpeek is an option for research and other non-diagnostic work. Mixpeek is not a medical device and has no FDA clearance. The key decision is whether you need a turnkey, FDA-cleared clinical tool or a flexible platform for non-diagnostic imaging applications.

    Best AI Medical Imaging Platforms: comparison at a glance

    #ToolBest forPricingKey differentiatorMain limit
    1AidocHospitals and radiology departments needing AI-assisted triage for critical findingsEnterprise pricing; per-scan or annual subscription modelsLargest FDA-cleared triage portfolio on this list (35 FDA AI device list entries as of September 2026), plus a cleared foundation model that triages multiple CT findings from one model, all running as a single always-on background layer.Focused on radiology (CT/X-ray); no pathology or dermatology
    2Viz.aiStroke centers and hospitals needing AI-powered neurovascular triage with proven outcomesEnterprise pricing; annual subscription per facilityCare coordination built into the product: not just detection but automated team notification and workflow orchestration that directly reduces time-to-treatment.Strongest in neurovascular care; other therapeutic areas are newer
    3PathAIPathology labs and pharmaceutical companies needing AI-assisted tissue analysis and biomarker researchEnterprise pricing; contact salesCombines an FDA-cleared primary diagnosis platform (AISight Dx) with biomarker scoring tools used in drug development by most of the top 15 biopharma companies, per PathAI.Pathology-only: no radiology or general imaging support
    4TempusHealth systems wanting AI that combines imaging with genomic and clinical data for precision medicineEnterprise pricing; contact salesPairs radiology and pathology imaging AI with genomic sequencing and a large clinical data library in one vendor, which few imaging companies can match.Platform-level commitment beyond imaging alone
    5Google Health AI (MedGemma)Research teams and developers building and validating their own medical imaging modelsMedGemma weights are free to download under Health AI Developer Foundations terms; Vertex AI hosting bills at Google Cloud ratesOpen, multimodal medical models you can fine-tune and host yourself, backed by Google's research on retinal screening and medical AI.Developer models, not cleared clinical products; Google says outputs must be independently verified
    6PaigeClinical pathology labs wanting FDA-authorized AI assistance for prostate biopsy reviewEnterprise pricing; per-slide or annual subscription for clinical deploymentsHolds the first FDA marketing authorization for an AI pathology product and now draws on Tempus's library of almost 7 million de-identified pathology slides.Currently limited to specific cancer types (prostate most mature)
    7Tempus Pixel (formerly Arterys)Cardiac imaging centers and oncology practices needing cloud-based AI for MR analysis and lesion trackingEnterprise pricing through Tempus; contact salesAn early cloud-based medical image analysis platform, now tied into Tempus's oncology data and pathology products.Sold as part of Tempus; the old arterys.com site still carries legacy branding
    8LunitHospitals and screening programs needing FDA-cleared AI for chest X-ray and mammography with strong global validation dataEnterprise pricing; annual subscription per modality per facilityLarge global footprint (10,000+ customer sites, per Lunit) and a deep publication record across chest X-ray and breast imaging, plus pathology tools for oncology research.Radiology products focus on chest X-ray and breast imaging
    9MixpeekResearch teams and health-tech companies building non-diagnostic imaging tools such as similar-case retrieval for research and training data managementBuild $25/mo with a $10 usage pool, Scale $250/mo with a $100 pool, Enterprise and customer-hosted on custom terms (as of 2026-11-10)A general-purpose multimodal indexing pipeline over your own object storage, which research and health-tech teams can configure for non-diagnostic imaging work without pre-built clinical models.Not a medical device and not FDA-cleared: not for diagnosis or clinical decision support
    10Qure.aiPublic health organizations and hospitals in resource-limited settings needing accessible, validated radiology AI for screening programsTiered pricing; affordable options designed for public health programs and developing marketsBuilt for resource-limited settings, with deployments in 105+ countries (per Qure.ai) and a strong record in public health TB screening programs.Less known in US/EU enterprise hospital markets

    The Mental Model That Makes Multimodal Search Click

    1

    Aidoc

    Radiology AI platform (aiOS) whose triage algorithms cover conditions such as stroke, pulmonary embolism, cervical spine fractures and aortic emergencies. Aidoc Medical has 35 entries on the FDA's AI-Enabled Medical Device List (September 2026 update), including the January 2026 clearance of its CARE foundation model for multi-condition CT triage. Aidoc says it is used in more than 1,600 medical centers (November 2026). It runs as a background layer on imaging studies and moves suspected critical findings up the radiologist's worklist.

    What Sets It Apart

    Largest FDA-cleared triage portfolio on this list (35 FDA AI device list entries as of September 2026), plus a cleared foundation model that triages multiple CT findings from one model, all running as a single always-on background layer.

    Strengths

    • +35 entries on the FDA AI device list as of September 2026, the most of any vendor here
    • +Used in more than 1,600 medical centers, per Aidoc (November 2026)
    • +Real-time triage that reprioritizes radiologist worklists
    • +Publishes customer outcome figures for PE and stroke notification times

    Limitations

    • -Focused on radiology (CT/X-ray); no pathology or dermatology
    • -Enterprise pricing not publicly available
    • -Requires PACS integration: not plug-and-play
    • -Limited customization; uses Aidoc's pre-built detection models only

    Real-World Use Cases

    • •Emergency department CT triage, flagging pulmonary embolism and intracranial hemorrhage within minutes of scan completion
    • •Incidental finding detection, catching early-stage aortic aneurysms or lung nodules that might be overlooked during primary reads
    • •Radiology workflow optimization, reprioritizing overnight worklists so critical cases are read first by attending radiologists
    • •Clinical outcomes tracking, measuring time-to-treatment improvements for stroke and PE cases across hospital systems

    Choose This When

    When your hospital needs a single vendor covering multiple radiology AI use cases with proven FDA clearance and clinical evidence across body regions.

    Skip This If

    When you need pathology, dermatology, or ophthalmology imaging AI, or when you want to build custom detection models on your own data.

    Integration Example

    // Aidoc integrates via PACS/DICOM: no direct API for end users
    // Typical deployment uses HL7/FHIR for worklist integration
    // Example: Consuming Aidoc alerts via FHIR Subscription
    const fhirSubscription = {
      resourceType: "Subscription",
      criteria: "Flag?category=aidoc-alert",
      channel: {
        type: "rest-hook",
        endpoint: "https://your-ehr.example.com/aidoc-alerts",
        payload: "application/fhir+json"
      }
    };
    Enterprise pricing; per-scan or annual subscription models
    Best for: Hospitals and radiology departments needing AI-assisted triage for critical findings
    Visit Website
    2

    Viz.ai

    FDA-cleared AI for stroke detection and care coordination. Analyzes CT angiograms to flag suspected large vessel occlusions (LVO) and alerts stroke teams through a mobile app. A 2023 JAMA Neurology stepped-wedge trial at four stroke centers reported an 11.2-minute reduction in door-to-groin time after Viz LVO was introduced. Viz.ai says its platform carries more than 50 FDA-cleared algorithms and is deployed in 2,000 US hospitals (2026), with areas beyond stroke such as hemorrhage, aneurysm and cardiomyopathy.

    What Sets It Apart

    Care coordination built into the product: not just detection but automated team notification and workflow orchestration that directly reduces time-to-treatment.

    Strengths

    • +Randomized trial (JAMA Neurology, 2023) reported an 11.2-minute door-to-groin reduction
    • +Automated care team notification via mobile app
    • +Cleared products beyond LVO include hemorrhage, aneurysm and a De Novo for hypertrophic cardiomyopathy
    • +Integrates with hospital PACS, EHR, and existing stroke workflows

    Limitations

    • -Strongest in neurovascular care; other therapeutic areas are newer
    • -Pricing is not published
    • -Requires hospital IT integration and clinical champions
    • -Not a general-purpose imaging AI platform

    Real-World Use Cases

    • •Large vessel occlusion stroke detection: automated LVO alerts sent directly to neurointerventionalists' phones within minutes of CT angiogram
    • •Stroke care coordination, synchronizing ER, neurology, and interventional teams with shared imaging and patient status via mobile app
    • •Pulmonary care coordination, routing suspected PE findings from CT pulmonary angiograms to the appropriate care team
    • •Door-to-groin time reduction, triggering cath lab prep before the patient physically arrives, based on AI-detected LVO

    Choose This When

    When reducing door-to-treatment time for stroke and other time-critical conditions is the primary goal, and you need care coordination alongside detection.

    Skip This If

    When you need general radiology AI covering many body regions, or when you want a platform for non-acute imaging workflows.

    Integration Example

    // Viz.ai uses DICOM routing + mobile app: no public REST API
    // Integration is via PACS router sending studies to Viz.ai node
    // Example: DICOM routing rule (MWL/HL7 config)
    {
      "dicomRouter": {
        "source": "CT_SCANNER_AET",
        "destination": "VIZ_AI_AET",
        "filters": {
          "modality": "CT",
          "bodyPart": ["HEAD", "NECK", "CHEST"]
        },
        "autoRoute": true
      }
    }
    Enterprise pricing; annual subscription per facility
    Best for: Stroke centers and hospitals needing AI-powered neurovascular triage with proven outcomes
    Visit Website
    3

    PathAI

    Digital pathology company whose AISight Dx platform received FDA 510(k) clearance for primary diagnosis in June 2025. PathAI also sells AI tools for clinical trials and biomarker work, and says 90% of the top 15 biopharma companies use its technology (November 2026). Roche signed a definitive agreement in May 2026 to acquire PathAI; PathAI's site still describes the deal as pending as of 2026-11-10.

    What Sets It Apart

    Combines an FDA-cleared primary diagnosis platform (AISight Dx) with biomarker scoring tools used in drug development by most of the top 15 biopharma companies, per PathAI.

    Strengths

    • +Purpose-built for pathology with deep oncology specialization
    • +Used by 90% of the top 15 biopharma companies, per PathAI (November 2026)
    • +Quantitative biomarker scoring for clinical trials (AIM-MASH received FDA qualification for MASH trials in December 2025)
    • +AISight Dx is FDA 510(k) cleared and being deployed by Labcorp and MedStar Health (2026)

    Limitations

    • -Pathology-only: no radiology or general imaging support
    • -Enterprise pricing, not accessible for small labs
    • -Requires whole-slide imaging scanner infrastructure
    • -Pending acquisition by Roche may change roadmap and commercial terms

    Real-World Use Cases

    • •Clinical trial biomarker quantification, scoring PD-L1 expression, tumor-infiltrating lymphocytes, and HER2 status on whole-slide images for patient stratification
    • •Drug development companion diagnostics, identifying visual biomarkers that predict response to novel therapies across Phase I-III trials
    • •Pathologist workflow augmentation: pre-screening slides to highlight regions of interest and suggest differential diagnoses for faster turnaround
    • •Cancer research data curation, building structured datasets from millions of annotated pathology images for model training and validation

    Choose This When

    When you are a pharma company running clinical trials that require AI-powered biomarker quantification, or a pathology lab wanting to augment diagnostic workflows with oncology-focused AI.

    Skip This If

    When you need radiology, ophthalmology, or non-pathology imaging AI, or when your lab has not yet invested in whole-slide imaging scanner infrastructure.

    Integration Example

    // PathAI integrates with LIS and digital pathology systems
    // Illustrative only: PathAI does not publish a public API; endpoint and fields are placeholders
    const response = await fetch("https://pathology-gateway.example.com/v1/cases", {
      method: "POST",
      headers: {
        "Authorization": "Bearer <PATHAI_API_KEY>",
        "Content-Type": "application/json"
      },
      body: JSON.stringify({
        caseId: "CASE-2026-001",
        slideUrls: ["s3://pathology-slides/case001_HE.svs"],
        stainType: "H&E",
        analysisType: "tumor_detection",
        priority: "routine"
      })
    });
    Enterprise pricing; contact sales
    Best for: Pathology labs and pharmaceutical companies needing AI-assisted tissue analysis and biomarker research
    Visit Website
    4

    Tempus

    Precision medicine company that combines molecular and clinical data with imaging. Its Pixel radiology software (from the 2022 Arterys acquisition) covers lung, breast, cardiac and therapy-response workflows, and it acquired the pathology AI company Paige in 2025. Tempus says Pixel is used by 100+ health systems (November 2026).

    What Sets It Apart

    Pairs radiology and pathology imaging AI with genomic sequencing and a large clinical data library in one vendor, which few imaging companies can match.

    Strengths

    • +Combines imaging AI with genomic and clinical data for holistic analysis
    • +One of the largest multimodal clinical and molecular data libraries, per Tempus
    • +FDA-authorized products include Tempus Pixel, ECG-AF, ECG-Low EF and the xT CDx genomic test
    • +Owns both radiology (Pixel) and pathology (Paige) imaging AI

    Limitations

    • -Platform-level commitment beyond imaging alone
    • -Enterprise pricing with complex licensing
    • -Data sharing requirements for full platform value
    • -Imaging is one part of a much broader genomics and data business

    Real-World Use Cases

    • •Multimodal cancer treatment planning, correlating tumor imaging features with genomic mutations and clinical history to inform oncologists' therapy decisions
    • •Clinical trial matching, using imaging phenotypes and molecular profiles to identify patients eligible for precision oncology trials
    • •Radiology-genomics research, discovering imaging biomarkers that correlate with specific genetic alterations across large patient cohorts
    • •Population health analytics, analyzing imaging and clinical data at scale to identify treatment patterns and outcomes across health systems

    Choose This When

    When your institution wants to combine imaging analysis with genomic and clinical data for comprehensive precision medicine, particularly in oncology.

    Skip This If

    When you only need standalone imaging AI without the broader precision medicine platform, or when data sharing agreements are a blocker for your organization.

    Integration Example

    // Illustrative pseudo-code: Tempus does not publish a public imaging SDK
    // Integration is arranged with Tempus; client and method names are placeholders
    const tempusClient = new TempusAPI({ apiKey: TEMPUS_KEY });
    
    const patientProfile = await tempusClient.patients.get({
      patientId: "PT-12345",
      include: ["imaging", "genomics", "clinical"]
    });
    
    // Correlate imaging features with genomic data
    const insights = await tempusClient.analytics.correlate({
      imagingFeatures: patientProfile.imaging.tumorFeatures,
      genomicProfile: patientProfile.genomics.mutations,
      analysisType: "treatment_recommendation"
    });
    Enterprise pricing; contact sales
    Best for: Health systems wanting AI that combines imaging with genomic and clinical data for precision medicine
    Visit Website
    5

    Google Health AI (MedGemma)

    Google's open MedGemma models (part of Health AI Developer Foundations) read medical text and images, with training data spanning chest X-ray, dermatology, fundus, histopathology, CT and MRI. Google states MedGemma is not clinical-grade and must be validated by developers. MedLM, its earlier Vertex AI medical model, was deprecated with access ending on or after September 29, 2025. Separately, Google licenses a diabetic retinopathy screening model to partners in India and Thailand.

    What Sets It Apart

    Open, multimodal medical models you can fine-tune and host yourself, backed by Google's research on retinal screening and medical AI.

    Strengths

    • +Open model weights on Hugging Face and Vertex AI Model Garden
    • +Multimodal: one model family covers several imaging types plus clinical text
    • +Retinopathy model supported more than 600,000 screenings as of October 2024, per Google
    • +Can be fine-tuned and hosted inside your own cloud project

    Limitations

    • -Developer models, not cleared clinical products; Google says outputs must be independently verified
    • -Earlier MedLM API was retired, so check model lifecycle before building
    • -Not a turnkey clinical solution; requires significant integration and validation work
    • -No FDA clearance for MedGemma

    Real-World Use Cases

    • •Diabetic retinopathy screening through Google's licensed partners (Forus Health, AuroLab, Perceptra) in India and Thailand
    • •Research prototypes that draft chest X-ray findings for radiologist review, built by fine-tuning MedGemma
    • •Dataset labeling and triage experiments across dermatology, fundus and histopathology images
    • •Medical image question answering in research and education tools, with outputs checked by clinicians

    Choose This When

    When you are a research team or developer that wants open medical foundation models to adapt and validate for your own imaging use case.

    Skip This If

    When you need FDA-cleared, production-ready clinical tools today, or when you do not have the team to validate models on your own data.

    Integration Example

    // MedGemma deployed from Vertex AI Model Garden to your own endpoint
    // Illustrative only: request shape depends on the serving container you deploy
    const ENDPOINT = "https://us-central1-aiplatform.googleapis.com/v1/projects/your-project/locations/us-central1/endpoints/your-medgemma-endpoint:predict";
    
    const response = await fetch(ENDPOINT, {
      method: "POST",
      headers: {
        "Authorization": "Bearer " + accessToken,
        "Content-Type": "application/json"
      },
      body: JSON.stringify({
        instances: [{
          prompt: "Describe the findings in this research chest X-ray.",
          image: { bytesBase64Encoded: xrayBase64 }
        }]
      })
    });
    // Research use only: outputs need independent clinical verification
    MedGemma weights are free to download under Health AI Developer Foundations terms; Vertex AI hosting bills at Google Cloud rates
    Best for: Research teams and developers building and validating their own medical imaging models
    Visit Website
    6

    Paige

    Digital pathology AI company, now part of Tempus (acquired 2025). Paige Prostate was the first AI pathology product authorized by the FDA (De Novo, September 2021) as an adjunct that flags areas of prostate biopsy slides suspicious for cancer. Paige also sells breast, GI and pan-cancer suites and the Virchow family of pathology foundation models.

    What Sets It Apart

    Holds the first FDA marketing authorization for an AI pathology product and now draws on Tempus's library of almost 7 million de-identified pathology slides.

    Strengths

    • +First AI pathology product authorized by the FDA (Paige Prostate, De Novo, 2021)
    • +In the FDA's review study, 16 pathologists using it detected cancer on 7.3% more individual slide images on average
    • +PanCancer suite trained on over 1.5 million slides, per Paige
    • +Product lines for prostate, breast, GI and pan-cancer work

    Limitations

    • -Currently limited to specific cancer types (prostate most mature)
    • -Requires whole-slide imaging infrastructure and digital pathology workflow
    • -Enterprise pricing not accessible for small community labs
    • -Now a Tempus company, so roadmap follows Tempus priorities

    Real-World Use Cases

    • •Prostate biopsy review: flagging areas suspicious for cancer on digitized H&E slides for the pathologist to examine
    • •Second-read quality assurance, running AI as a parallel reader to flag cases where pathologist and AI disagree for additional review
    • •High-volume lab throughput, prioritizing positive cases in labs processing hundreds of prostate biopsies daily
    • •Pathologist training, using AI-annotated slides as educational tools for residents learning cancer morphology

    Choose This When

    When you need FDA-authorized AI assistance for prostate biopsy review in clinical pathology workflows, or when regulatory status is a hard requirement.

    Skip This If

    When you need AI for drug development and clinical trial biomarker quantification (PathAI is stronger), or when your lab has not adopted digital pathology workflows.

    Integration Example

    // Paige integrates with digital pathology systems via HL7/DICOM
    // Illustrative only: Paige does not publish a public API; endpoint and fields are placeholders
    const response = await fetch("https://pathology-gateway.example.com/v1/analyze", {
      method: "POST",
      headers: {
        "Authorization": "Bearer <PAIGE_API_KEY>",
        "Content-Type": "application/json"
      },
      body: JSON.stringify({
        slideId: "SLIDE-2026-0042",
        slideUrl: "s3://pathology/slides/case42_HE.svs",
        analysisType: "prostate_cancer_detection",
        returnHeatmap: true
      })
    });
    Enterprise pricing; per-slide or annual subscription for clinical deployments
    Best for: Clinical pathology labs wanting FDA-authorized AI assistance for prostate biopsy review
    Visit Website
    7

    Tempus Pixel (formerly Arterys)

    Cloud-based radiology software that Tempus acquired with Arterys in 2022. Tempus Pixel provides viewing and automated reporting of cardiac MR images, covering flow visualization, functional analysis and tissue characterization, and an updated version received FDA 510(k) clearance in September 2025 for generating T1 and T2 inline maps. Tempus lists lung, breast, prostate and therapy-response modules alongside cardio.

    What Sets It Apart

    An early cloud-based medical image analysis platform, now tied into Tempus's oncology data and pathology products.

    Strengths

    • +FDA-cleared cardiac MR analysis, updated in September 2025 with T1 and T2 inline maps
    • +Cloud-based viewer: no on-premise hardware required
    • +20+ algorithms across cardio, lung, breast and oncology, per Tempus (November 2026)
    • +Integrates with PACS, EHR, worklist and dictation systems, per Tempus

    Limitations

    • -Sold as part of Tempus; the old arterys.com site still carries legacy branding
    • -Cloud deployment may not meet all data residency requirements
    • -Fewer FDA AI device list entries than Aidoc (6 under Arterys as of September 2026)
    • -Cardiac MRI is a niche use case for most hospitals

    Real-World Use Cases

    • •Cardiac MR quantification: automated functional analysis, flow visualization and T1/T2 tissue mapping
    • •Oncology therapy response, segmenting and tracking lesions across time points with automated RECIST reporting
    • •Remote cardiac imaging reads, enabling cardiologists to access AI-enhanced MRI analysis from any location via cloud viewer
    • •Longitudinal cardiac monitoring, tracking changes in cardiac function across serial MRI exams with automated measurements

    Choose This When

    When you want cloud-based cardiac MR AI without on-premise hardware, or when you already work with Tempus on oncology and want imaging in the same relationship.

    Skip This If

    When you need on-premise deployment for data sovereignty, or when cardiac MRI is not a priority and you need broader radiology coverage.

    Integration Example

    // Tempus Pixel cloud viewer: DICOM push to cloud
    // Illustrative only: gateway host and AE titles are assigned during onboarding
    {
      "dicomGateway": {
        "localAET": "PACS_MAIN",
        "remoteAET": "PIXEL_CLOUD",
        "remoteHost": "dicom-gateway.example.com",
        "remotePort": 4242,
        "modalities": ["MR"],
        "bodyParts": ["HEART"],
        "autoForward": true
      }
    }
    Enterprise pricing through Tempus; contact sales
    Best for: Cardiac imaging centers and oncology practices needing cloud-based AI for MR analysis and lesion tracking
    Visit Website
    8

    Lunit

    South Korean AI company focused on cancer screening and precision oncology. US FDA clearances cover Lunit INSIGHT CXR Triage (2021), INSIGHT MMG for 2D mammography (2021) and INSIGHT DBT for 3D breast tomosynthesis (2023, updated 2026). Lunit reports 10,000+ customer sites in 70+ countries and 700+ publications (November 2026), and it acquired the breast imaging company Volpara in 2024.

    What Sets It Apart

    Large global footprint (10,000+ customer sites, per Lunit) and a deep publication record across chest X-ray and breast imaging, plus pathology tools for oncology research.

    Strengths

    • +FDA-cleared products for chest X-ray triage, 2D mammography and 3D tomosynthesis
    • +10,000+ customer sites in 70+ countries, per Lunit (November 2026)
    • +700+ publications, per Lunit (November 2026)
    • +Volpara acquisition (2024) added breast density software and a US customer base

    Limitations

    • -Radiology products focus on chest X-ray and breast imaging
    • -US chest X-ray clearance is for triage only (CXR Triage)
    • -Requires PACS integration similar to other clinical AI tools
    • -Enterprise pricing; not available for individual clinicians

    Real-World Use Cases

    • •Tuberculosis screening programs, using chest X-ray AI where it is authorized in high-burden regions with few radiologists
    • •Breast cancer screening support, showing AI findings to radiologists reading 2D mammograms and 3D tomosynthesis
    • •Precision oncology research, using Lunit SCOPE to analyze tumor microenvironment and IHC markers on pathology slides
    • •Emergency department chest X-ray triage, prioritizing abnormal chest films for faster radiologist interpretation

    Choose This When

    When you need widely deployed AI for chest X-ray screening (especially TB programs outside the US) or for 2D and 3D breast screening.

    Skip This If

    When you need AI for modalities beyond chest X-ray and breast imaging, such as head CT or cardiac MR.

    Integration Example

    // Lunit INSIGHT integrates via DICOM routing from PACS
    // Illustrative only: Lunit does not publish a public API; endpoint and fields are placeholders
    const response = await fetch("https://imaging-gateway.example.com/v1/inference", {
      method: "POST",
      headers: {
        "Authorization": "Bearer <LUNIT_API_KEY>",
        "Content-Type": "application/json"
      },
      body: JSON.stringify({
        studyId: "STUDY-2026-789",
        modality: "CR",  // chest radiograph
        dicomUrl: "dicom://pacs.hospital.org/study/789",
        product: "INSIGHT_CXR",
        returnHeatmap: true
      })
    });
    Enterprise pricing; annual subscription per modality per facility
    Best for: Hospitals and screening programs needing FDA-cleared AI for chest X-ray and mammography with strong global validation data
    Visit Website
    9

    Mixpeek

    Our Pick
    Try MVS

    Multimodal indexing and retrieval platform that teams can use to build non-diagnostic imaging applications. Mixpeek is not a medical device, has no FDA clearance and makes no diagnostic claims. It indexes images (for example PNG or JPEG exported from DICOM studies), video, audio and documents from your object storage with configurable feature extractors, so you can run similarity search and retrieval across research datasets.

    What Sets It Apart

    A general-purpose multimodal indexing pipeline over your own object storage, which research and health-tech teams can configure for non-diagnostic imaging work without pre-built clinical models.

    Strengths

    • +One pipeline for images, video, audio and documents in your object storage
    • +Similarity search across research imaging datasets through one API
    • +Configurable feature extractors: swap models without re-architecting
    • +Customer-hosted deployment keeps data and vectors in your own cloud account

    Limitations

    • -Not a medical device and not FDA-cleared: not for diagnosis or clinical decision support
    • -No pre-built clinical detection models (stroke, cancer, etc.)
    • -No HIPAA BAA offered today, per Mixpeek docs; contact sales for PHI requirements
    • -No native DICOM or PACS integration; export studies to standard image formats first

    Real-World Use Cases

    • •Research case retrieval, searching de-identified imaging archives for visually similar studies for research review and teaching files
    • •Training data curation, organizing and deduplicating large medical image sets for ML model training with embedding-based clustering
    • •Medical education platforms, enabling students to search imaging databases by visual similarity and anatomical features
    • •Clinical trial image management, indexing and retrieving imaging data across multi-site trials with custom metadata extraction

    Choose This When

    When you are building a custom medical imaging application (similar case retrieval, dataset curation, or research tools) and need a flexible multimodal platform rather than a turnkey clinical product.

    Skip This If

    When you need FDA-cleared clinical decision support for direct patient care, or when you want pre-built detection models for specific conditions without custom development.

    Integration Example

    import { Mixpeek } from "mixpeek";
    
    const client = new Mixpeek({
      apiKey: process.env.MIXPEEK_API_KEY,
      namespace: "imaging-research"
    });
    
    // Index de-identified images exported from DICOM (PNG/JPEG) in your bucket
    await client.documents.uploadDocuments({
      collectionId: "col_radiology_research",
      documents: [
        {
          url: "s3://research-imaging/ct_chest_0001.png",
          metadata: { modality: "CT", bodyPart: "chest" }
        }
      ]
    });
    
    // Find visually similar research cases
    const similar = await client.retrievers.executeRetriever({
      retrieverId: "ret_similar_cases",
      query: "s3://research-imaging/query_case.png"
    });
    Build $25/mo with a $10 usage pool, Scale $250/mo with a $100 pool, Enterprise and customer-hosted on custom terms (as of 2026-11-10)
    Best for: Research teams and health-tech companies building non-diagnostic imaging tools such as similar-case retrieval for research and training data management
    Get started
    10

    Qure.ai

    Radiology AI company focused on making imaging AI accessible in resource-limited settings. Qure.ai reports 26 FDA-cleared indications across 9 chest X-ray and CT products (February 2026), including qXR for chest X-ray and qER for head CT. It says it serves 5,500+ sites in 105+ countries (November 2026), with strong traction in tuberculosis screening programs.

    What Sets It Apart

    Built for resource-limited settings, with deployments in 105+ countries (per Qure.ai) and a strong record in public health TB screening programs.

    Strengths

    • +26 FDA-cleared indications across 9 products for X-ray and CT, per Qure.ai (February 2026)
    • +5,500+ sites in 105+ countries, per Qure.ai (November 2026)
    • +Strong public health focus: TB screening at population scale
    • +Covers the TB care cascade (qTrack) as well as image reading

    Limitations

    • -Less known in US/EU enterprise hospital markets
    • -Fewer algorithms than Aidoc for comprehensive radiology AI
    • -Limited pathology and non-radiology imaging coverage
    • -No mammography product listed (November 2026)

    Real-World Use Cases

    • •National TB screening programs, deploying chest X-ray AI across community health centers to screen populations without radiologists
    • •Emergency head CT triage, detecting intracranial hemorrhage, midline shift, and fractures in emergency departments with limited specialist coverage
    • •Lung nodule management, flagging and quantifying nodules on chest X-ray and CT for follow-up
    • •Mobile screening vans, running AI analysis on portable X-ray equipment in remote and rural healthcare settings

    Choose This When

    When you need radiology AI that works in low-resource environments, supports public health screening programs, or need affordable deployment in developing healthcare markets.

    Skip This If

    When you need comprehensive enterprise radiology AI for a well-resourced hospital system, or when mammography and advanced cardiac imaging are priorities.

    Integration Example

    // Qure.ai offers cloud and on-site deployment
    // Illustrative only: endpoint and fields are placeholders, not a published Qure.ai API
    const response = await fetch("https://imaging-gateway.example.com/v2/analyze", {
      method: "POST",
      headers: {
        "Authorization": "Bearer <QURE_API_KEY>",
        "Content-Type": "application/json"
      },
      body: JSON.stringify({
        studyUid: "1.2.840.113619.2.55.12345",
        modality: "CR",
        product: "qXR",  // chest X-ray AI
        returnFindings: true,
        returnHeatmap: true,
        callbackUrl: "https://your-system.example.com/results"
      })
    });
    Tiered pricing; affordable options designed for public health programs and developing markets
    Best for: Public health organizations and hospitals in resource-limited settings needing accessible, validated radiology AI for screening programs
    Visit Website

    Which one fits your use case?

    Find your situation in the first column. The last column says when the pick is the wrong call.

    Choose it whenPickLook elsewhere when
    Your hospital needs a single vendor covering multiple radiology AI use cases with proven FDA clearance and clinical evidence across body regions.AidocYou need pathology, dermatology, or ophthalmology imaging AI, or when you want to build custom detection models on your own data.
    Reducing door-to-treatment time for stroke and other time-critical conditions is the primary goal, and you need care coordination alongside detection.Viz.aiYou need general radiology AI covering many body regions, or when you want a platform for non-acute imaging workflows.
    You are a pharma company running clinical trials that require AI-powered biomarker quantification, or a pathology lab wanting to augment diagnostic workflows with oncology-focused AI.PathAIYou need radiology, ophthalmology, or non-pathology imaging AI, or when your lab has not yet invested in whole-slide imaging scanner infrastructure.
    Your institution wants to combine imaging analysis with genomic and clinical data for comprehensive precision medicine, particularly in oncology.TempusYou only need standalone imaging AI without the broader precision medicine platform, or when data sharing agreements are a blocker for your organization.
    You are a research team or developer that wants open medical foundation models to adapt and validate for your own imaging use case.Google Health AI (MedGemma)You need FDA-cleared, production-ready clinical tools today, or when you do not have the team to validate models on your own data.
    You need FDA-authorized AI assistance for prostate biopsy review in clinical pathology workflows, or when regulatory status is a hard requirement.PaigeYou need AI for drug development and clinical trial biomarker quantification (PathAI is stronger), or when your lab has not adopted digital pathology workflows.
    You want cloud-based cardiac MR AI without on-premise hardware, or when you already work with Tempus on oncology and want imaging in the same relationship.Tempus Pixel (formerly Arterys)You need on-premise deployment for data sovereignty, or when cardiac MRI is not a priority and you need broader radiology coverage.
    You need widely deployed AI for chest X-ray screening (especially TB programs outside the US) or for 2D and 3D breast screening.LunitYou need AI for modalities beyond chest X-ray and breast imaging, such as head CT or cardiac MR.
    Managed Mixpeek

    Put AI medical imaging to work

    Connect a bucket and Mixpeek runs the whole AI medical imaging pipeline for you: extraction, indexing, and search over your own objects. No models to wire up, nothing to host.

    Start with Managed
    MVS · bring your own

    Already have vectors?

    Keep your embeddings on your own cloud and run dense, sparse, and BM25 search directly on object storage. From $25/mo.

    Start with MVS

    Frequently Asked Questions

    What is the best AI medical imaging platform in 2026?

    For FDA-cleared clinical radiology triage, Aidoc is the strongest pick in 2026: 35 entries on the FDA AI device list (September 2026) and use in more than 1,600 medical centers, per Aidoc. For digital pathology, PathAI (being acquired by Roche) and Paige (now part of Tempus) lead whole-slide image analysis. For teams building custom, non-diagnostic imaging applications such as similar-case retrieval for research, cohort curation or training-data search, a multimodal indexing platform like Mixpeek can turn imaging archives in object storage into searchable embeddings. Mixpeek is not a medical device. Pick by regulatory need first: diagnosis requires FDA-cleared tools, research and retrieval do not.

    How do I search medical images by visual similarity?

    Similar-case retrieval works by converting each image into a vector embedding with a vision model (see image embeddings) and indexing those vectors for nearest-neighbor search. A query image is embedded the same way, and the index returns the most similar studies with their metadata. Platforms like Mixpeek run this pipeline directly over DICOM-derived images in your object storage, and the best multimodal embedding models list compares the encoder options. For research archives, pairing embeddings with metadata filters (modality, body region, finding) keeps retrieval clinically meaningful.

    Is AI for medical imaging FDA approved?

    Many AI medical imaging products have received FDA clearance through the 510(k) pathway or De Novo authorization. The FDA's AI-Enabled Medical Device List held 1,614 devices at its September 2026 update, and 1,230 of them were radiology devices. The FDA notes the list is not comprehensive. 'Clearance' differs from 'approval': most devices are cleared through the 510(k) pathway, which shows substantial equivalence to an existing device and usually involves less clinical evidence than premarket approval. Always verify current status in the FDA databases.

    Can general AI platforms be used for medical imaging?

    General platforms like Mixpeek can power custom medical imaging applications (search, classification, retrieval) but should not be used as standalone clinical decision support without proper validation and regulatory approval. They are well-suited for research, training data management, similar case retrieval, and building applications that are reviewed by clinical professionals.

    What compliance requirements apply to medical imaging AI?

    Key requirements include HIPAA compliance (US), GDPR (EU), FDA clearance for clinical use (US), CE marking (EU), and healthcare-specific data handling standards. Self-hosted deployment options are critical for meeting data residency requirements. All medical AI should be validated on representative patient populations before clinical deployment.

    How accurate is AI at detecting diseases in medical images?

    Accuracy depends on the task, the imaging modality and the patient population, so check the study behind each product. In the study the FDA reviewed for Paige Prostate, 16 pathologists using the software detected cancer on 7.3% more individual slide images on average, and the study did not measure the effect on final patient diagnosis. The 2023 JAMA Neurology trial of Viz LVO reported a workflow measure, an 11.2-minute door-to-groin reduction. Most cleared products are authorized as aids to a clinician, so validate any tool on your own population before clinical use.

    Which AI models score highest on medical imaging benchmarks?

    Most published scores on medical imaging benchmarks come from the vendors themselves. On 12 November 2026 DIAGENS (HKEX: 2526) reported that its iMed-6.0 Thoth model placed first in the multimodal API evaluation of MedBench, the medical benchmark from Shanghai AI Laboratory, with 64.4 overall, and scored 74.9% on the Health and Medicine section of MMMU. The same release says a CT model built on its Aegis variant flags 509 chest and abdominal findings with a macro-averaged AUC of 0.855, validated on about 40,000 CT exams from partner hospitals (DIAGENS release). These figures are self-reported, and the release names no FDA, CE or NMPA clearance. Benchmark scores measure question answering on test sets, so for clinical use check the FDA AI-Enabled Medical Device List and validate on your own patient population. Mixpeek is not a medical device. Research teams use it to index de-identified images in their own storage for similar-case search, as described above.

    See how Mixpeek handles this

    Purpose-built for ai medical imaging platforms, not bolted on.

    Clinical NLP & Medical AI

    Mixpeek's dedicated page for this capability: architecture, benchmarks, and how it works.

    Explore Clinical NLP & Medical AI

    Talk to a Mixpeek engineer: free

    30 minutes. Bring your use case and we'll tell you exactly what would work and what wouldn't.

    Schedule a Free Call

    Explore Other Curated Lists

    industry specific

    Best AI Legal Document Review Tools

    A comparison of AI platforms for contract analysis, legal document review, and due diligence. Evaluated on extraction accuracy, clause detection, and integration with legal workflows.

    10 tools rankedView List
    industry specific

    Best AI Platforms for Advertising Technology

    Which AI platforms lead ad tech in 2026? DoubleVerify and IAS for brand suitability and verification, Zefr and Channel Factory for YouTube and social video, Peer39, Anoki and Wurl for CTV contextual signals, GumGum and Silverpush as Grapeshot replacements, and Vidmob and Pencil for creative intelligence. Mixpeek is the developer layer for teams building their own IAB 3.1 signals.

    13 tools rankedView List
    industry specific

    Best AI Digital Asset Management Tools

    We evaluated leading AI-powered digital asset management platforms on auto-tagging accuracy, search capabilities, and workflow automation. This guide covers solutions for managing large media libraries with intelligent organization.

    11 tools rankedView List